eCite Digital Repository

EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography


Lang, RM and Badano, LP and Tsang, W and Adams, DH and Agricola, E and Buck, T and Faletra, FF and Franke, A and Hung, J and Perez de Isla, L and Kamp, O and Kasprzak, JD and Lancellotti, P and Marwick, TH and McCulloch, ML and Monaghan, MJ and Nihoyannopoulos, P and Pandian, NG and Pellikka, PA and Pepi, M and Roberson, DA and Shernan, SK and Shirali, GS and Sugeng, L and Ten Cate, FJ and Vannan, MA and Zamorano, JL and Zoghbi, WA, EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography, European Heart Journal, 13, (1) pp. 1-46. ISSN 0195-668X (2012) [Refereed Article]

Copyright Statement

Copyright 2012 Oxford University Press

DOI: doi:10.1093/ehjci/jer316


Context Current guidelines recommend the use of aldosterone antagonists (AA) in patients with moderately severe to severe symptoms [New York Heart Association (NYHA) class III to IV] and systolic heart failure.
Objective To determine the efficacy of AA in improving ejection fraction (EF) and functional capacity and to assess whether this effect was influenced by baseline NYHA classification.
Study design Meta-analysis of randomized controlled trials. Data extraction performed independently by two researchers.
Data Sources MEDLINE and the Cochrane Library.
Study Selection Prospective randomized controlled trials using AA were included if there was a clear description of the baseline NYHA classification and change in EF in patients from study initiation to completion.
Results Data from 1,575 patients enrolled in fourteen studies were included. Overall, there was a weighted mean improvement in EF of 3.2% and in NYHA classification of 0.13 in subjects treated with AA when compared to controls (p<0.001). A mixed effects meta-regression analysis revealed that baseline NYHA was not predictive of improvement in EF (p=0.67) nor NYHA status (p=0.18).
Conclusions The results of this meta-analysis suggest that AA is associated with significant improvements in EF and functional class independent of baseline functional capacity. This supports and expands on the recently published EMPHASIS-HF trial and suggests that the current restriction of AA use to patients with NYHA class III-IV symptoms should be reconsidered.

Item Details

Item Type:Refereed Article
Keywords:echocardiography, two-dimensional, three-dimensional, transthoracic, transesophageal
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Cardiology (incl. cardiovascular diseases)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Marwick, TH (Professor Tom Marwick)
ID Code:91499
Year Published:2012
Web of Science® Times Cited:208
Deposited By:Menzies Institute for Medical Research
Deposited On:2014-05-21
Last Modified:2015-03-24

Repository Staff Only: item control page